Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )
31 May 2026

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer ( Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA )
27 Apr 2026

Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer

Dr Angelica Loskog - Uppsala University, Uppsala, Sweden
Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer ( Dr Angelica Loskog -  Uppsala University, Uppsala, Sweden )
24 Apr 2026

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer

Dr Manuel Hidalgo - NYU Langone Health, New York, USA
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer ( Dr Manuel Hidalgo - NYU Langone Health, New York, USA )
24 Apr 2026

Using lived experience of pancreatic cancer to build faith-based support

Olayinka Sowemimo–Coker - Pancreatic cancer survivor and Founder of DChanger
Using lived experience of pancreatic cancer to build faith-based support ( Olayinka Sowemimo–Coker - Pancreatic cancer survivor and Founder of DChanger )
27 Jan 2026

Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma

Dr Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma ( Dr Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
15 Jan 2026

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA
Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma ( Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA )
17 Dec 2025

Precision approaches to treating HPB cancers

Dr Milind Javle - The University of Texas MD Anderson Cancer Center Houston, Texas, EE. UU
Precision approaches to treating HPB cancers ( Dr Milind Javle - The University of Texas MD Anderson Cancer Center Houston, Texas, EE. UU )
7 Nov 2025

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )
19 Oct 2025

The hidden biology of addiction and cancer

Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA
The hidden biology of addiction and cancer ( Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA )
16 Jul 2025

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
11 Jul 2025

Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer

Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt, Germany
Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer ( Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt, Germany )
1 Jun 2025